155 related articles for article (PubMed ID: 26864615)
1. Silodosin inhibits prostate cancer cell growth via ELK1 inactivation and enhances the cytotoxic activity of gemcitabine.
Kawahara T; Aljarah AK; Shareef HK; Inoue S; Ide H; Patterson JD; Kashiwagi E; Han B; Li Y; Zheng Y; Miyamoto H
Prostate; 2016 Jun; 76(8):744-56. PubMed ID: 26864615
[TBL] [Abstract][Full Text] [Related]
2. Silodosin inhibits the growth of bladder cancer cells and enhances the cytotoxic activity of cisplatin via ELK1 inactivation.
Kawahara T; Ide H; Kashiwagi E; Patterson JD; Inoue S; Shareef HK; Aljarah AK; Zheng Y; Baras AS; Miyamoto H
Am J Cancer Res; 2015; 5(10):2959-68. PubMed ID: 26693052
[TBL] [Abstract][Full Text] [Related]
3. ELK1 is up-regulated by androgen in bladder cancer cells and promotes tumor progression.
Kawahara T; Shareef HK; Aljarah AK; Ide H; Li Y; Kashiwagi E; Netto GJ; Zheng Y; Miyamoto H
Oncotarget; 2015 Oct; 6(30):29860-76. PubMed ID: 26342199
[TBL] [Abstract][Full Text] [Related]
4. Silodosin inhibits noradrenaline-activated transcription factors Elk1 and SRF in human prostate smooth muscle.
Hennenberg M; Strittmatter F; Beckmann C; Rutz B; Füllhase C; Waidelich R; Montorsi F; Hedlund P; Andersson KE; Stief CG; Gratzke C
PLoS One; 2012; 7(11):e50904. PubMed ID: 23226423
[TBL] [Abstract][Full Text] [Related]
5. Androgen receptor knockdown enhances prostate cancer chemosensitivity by down-regulating FEN1 through the ERK/ELK1 signalling pathway.
Xie W; Li S; Guo H; Zhang J; Tu M; Wang R; Lin B; Wu Y; Wang X
Cancer Med; 2023 Jul; 12(14):15317-15336. PubMed ID: 37326412
[TBL] [Abstract][Full Text] [Related]
6. ELK1 promotes urothelial tumorigenesis in the presence of an activated androgen receptor.
Inoue S; Ide H; Mizushima T; Jiang G; Kawahara T; Miyamoto H
Am J Cancer Res; 2018; 8(11):2325-2336. PubMed ID: 30555747
[TBL] [Abstract][Full Text] [Related]
7. The ETS domain transcription factor ELK1 directs a critical component of growth signaling by the androgen receptor in prostate cancer cells.
Patki M; Chari V; Sivakumaran S; Gonit M; Trumbly R; Ratnam M
J Biol Chem; 2013 Apr; 288(16):11047-65. PubMed ID: 23426362
[TBL] [Abstract][Full Text] [Related]
8. MED19 alters AR occupancy and gene expression in prostate cancer cells, driving MAOA expression and growth under low androgen.
Weber H; Ruoff R; Garabedian MJ
PLoS Genet; 2021 Jan; 17(1):e1008540. PubMed ID: 33513133
[TBL] [Abstract][Full Text] [Related]
9. Strategy for Tumor-Selective Disruption of Androgen Receptor Function in the Spectrum of Prostate Cancer.
Rosati R; Polin L; Ducker C; Li J; Bao X; Selvakumar D; Kim S; Xhabija B; Larsen M; McFall T; Huang Y; Kidder BL; Fribley A; Saxton J; Kakuta H; Shaw P; Ratnam M
Clin Cancer Res; 2018 Dec; 24(24):6509-6522. PubMed ID: 30185422
[TBL] [Abstract][Full Text] [Related]
10. The Amino-terminal Domain of the Androgen Receptor Co-opts Extracellular Signal-regulated Kinase (ERK) Docking Sites in ELK1 Protein to Induce Sustained Gene Activation That Supports Prostate Cancer Cell Growth.
Rosati R; Patki M; Chari V; Dakshnamurthy S; McFall T; Saxton J; Kidder BL; Shaw PE; Ratnam M
J Biol Chem; 2016 Dec; 291(50):25983-25998. PubMed ID: 27793987
[TBL] [Abstract][Full Text] [Related]
11. The role of NFATc1 in prostate cancer progression: cyclosporine A and tacrolimus inhibit cell proliferation, migration, and invasion.
Kawahara T; Kashiwagi E; Ide H; Li Y; Zheng Y; Ishiguro H; Miyamoto H
Prostate; 2015 May; 75(6):573-84. PubMed ID: 25631176
[TBL] [Abstract][Full Text] [Related]
12. Relative cytotoxic potencies and cell death mechanisms of α1 -adrenoceptor antagonists in prostate cancer cell lines.
Forbes A; Anoopkumar-Dukie S; Chess-Williams R; McDermott C
Prostate; 2016 Jun; 76(8):757-66. PubMed ID: 26880388
[TBL] [Abstract][Full Text] [Related]
13. The ternary complex factor protein ELK1 is an independent prognosticator of disease recurrence in prostate cancer.
Pardy L; Rosati R; Soave C; Huang Y; Kim S; Ratnam M
Prostate; 2020 Feb; 80(2):198-208. PubMed ID: 31794091
[TBL] [Abstract][Full Text] [Related]
14. Effect of Silodosin, an Alpha1A-Adrenoceptor Antagonist, on Ventral Prostatic Hyperplasia in the Spontaneously Hypertensive Rat.
Shimizu S; Shimizu T; Tsounapi P; Higashi Y; Martin DT; Nakamura K; Honda M; Inoue K; Saito M
PLoS One; 2015; 10(8):e0133798. PubMed ID: 26308715
[TBL] [Abstract][Full Text] [Related]
15. Expression of Phospho-ELK1 and Its Prognostic Significance in Urothelial Carcinoma of the Upper Urinary Tract.
Inoue S; Ide H; Fujita K; Mizushima T; Jiang G; Kawahara T; Yamaguchi S; Fushimi H; Nonomura N; Miyamoto H
Int J Mol Sci; 2018 Mar; 19(3):. PubMed ID: 29518027
[TBL] [Abstract][Full Text] [Related]
16. Estrogen induces androgen-repressed SOX4 expression to promote progression of prostate cancer cells.
Yang M; Wang J; Wang L; Shen C; Su B; Qi M; Hu J; Gao W; Tan W; Han B
Prostate; 2015 Sep; 75(13):1363-75. PubMed ID: 26015225
[TBL] [Abstract][Full Text] [Related]
17. Reduced FRG1 expression promotes prostate cancer progression and affects prostate cancer cell migration and invasion.
Tiwari A; Mukherjee B; Hassan MK; Pattanaik N; Jaiswal AM; Dixit M
BMC Cancer; 2019 Apr; 19(1):346. PubMed ID: 30975102
[TBL] [Abstract][Full Text] [Related]
18. Effects of α
Nagata Y; Kawahara T; Goto T; Inoue S; Teramoto Y; Jiang G; Fujimoto N; Miyamoto H
Am J Cancer Res; 2020; 10(12):4386-4398. PubMed ID: 33415006
[TBL] [Abstract][Full Text] [Related]
19. Naftopidil, a selective {alpha}1-adrenoceptor antagonist, suppresses human prostate tumor growth by altering interactions between tumor cells and stroma.
Hori Y; Ishii K; Kanda H; Iwamoto Y; Nishikawa K; Soga N; Kise H; Arima K; Sugimura Y
Cancer Prev Res (Phila); 2011 Jan; 4(1):87-96. PubMed ID: 21205739
[TBL] [Abstract][Full Text] [Related]
20. Grape seed extract inhibits EGF-induced and constitutively active mitogenic signaling but activates JNK in human prostate carcinoma DU145 cells: possible role in antiproliferation and apoptosis.
Tyagi A; Agarwal R; Agarwal C
Oncogene; 2003 Mar; 22(9):1302-16. PubMed ID: 12618755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
